Search results
Results from the WOW.Com Content Network
Enfortumab vedotin, sold under the brand name Padcev, is an antibody-drug conjugate [6] used for the treatment of urothelial cancer. [4] [7] It is a nectin-4-directed antibody and microtubule inhibitor conjugate. [4] [7] Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker. [5]
Enfortumab vedotin: Iptacopan: To treat paroxysmal nocturnal hemoglobinuria [4] Ivosidenib: Lecanemab: To treat Alzheimer's disease [4] Miglustat: Nedosiran: To lower urinary oxalate levels in primary hyperoxaluria type 1 and relatively preserved kidney function [4] Nirogacestat: To treat desmoid tumors [4] Pembrolizumab: Sutimlimab: Talquetamab
The FDA accepts Seattle Genetics (SGEN) and Astellas' BLA for enfortumab vedotin under a priority review to treat advanced/metastatic urothelial cancer. A verdict is pending on Mar 15, 2020.
In International Nonproprietary Names for MMAE-MAB-conjugates, the name vedotin refers to MMAE plus its linking structure to the antibody. [1] It is a potent antimitotic drug derived from peptides occurring in marine shell-less mollusc Dolabella auricularia called dolastatins which show potent activity in preclinical studies, both in vitro and ...
The European Medicines Agency accepts Seagen (SGEN) and Astellas Pharma's marketing application for enfortumab vedotin for treating adult patients with advanced/metastatic urothelial cancer.
Health Canada Approves ADCETRIS ® (Brentuximab Vedotin) for the Treatment of Relapsed or Refractory Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell Lymphoma (sALCL) - ADCETRIS is the ...
Seribantumab [40] mab: human: ERBB3 (HER3) cancer Setoxaximab [40] mab: chimeric: E. coli shiga toxin type-2: Setrusumab [26] mab: human: sclerostin (SOST) Sevirumab: human: cytomegalovirus: cytomegalovirus infection Sibrotuzumab: mab: humanized: FAP (gene) (FAP) cancer SGN-CD19A: mab: humanized: CD19: acute lymphoblastic leukemia and B-cell ...
Tisotumab vedotin, sold under the brand name Tivdak, is an antibody-drug conjugate used to treat cervical cancer. [1] It is a combination of tisotumab, a monoclonal antibody against tissue factor , and monomethyl auristatin E (MMAE), a potent inhibitor of cell division .